<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00581828</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0159</org_study_id>
    <secondary_id>05-1235-02</secondary_id>
    <nct_id>NCT00581828</nct_id>
  </id_info>
  <brief_title>Does Treatment of Hypovitaminosis D Increase Calcium Absorption?</brief_title>
  <official_title>Does Treatment of Hypovitaminosis D Increase Calcium Absorption?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to perform a one-year study designed to assess whether treatment of&#xD;
      hypovitaminosis D increases intestinal absorption of calcium, subsequent retention of calcium&#xD;
      within bone, decreases bone turnover, and favorably impacts upon skeletal muscle mass,&#xD;
      functional status, measures of physical function and quality of life. I hypothesize that&#xD;
      treatment of hypovitaminosis D results in improved intestinal calcium absorption, greater&#xD;
      retention of calcium within the bone reservoir and improved physical function, quality of&#xD;
      life and muscle mass.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postmenopausal women with vitamin D insufficiency will participate in this one-year study. We&#xD;
      will study the change in intestinal calcium absorption from baseline (vitamin D&#xD;
      insufficiency) to follow up (vitamin D repletion and whether increased absorption results in&#xD;
      subsequent increased retention of calcium within bone over the one-year interval as measured&#xD;
      by bone densitometry. We will also study the effect of vitamin D repletion upon whole body&#xD;
      muscle mass, quality of life and physical function.&#xD;
&#xD;
      A review of medical records and a screening visit will determine eligibility. Eligible and&#xD;
      consenting subjects will present to the GCRC in the early morning and following baseline&#xD;
      labs, will consume breakfast with a glass of orange juice enriched with a stable calcium&#xD;
      isotope, and will receive 3 mg of another stable calcium isotope by intravenous injection.&#xD;
      Over the next eight hours, blood will be taken a total of 9 more times and over the first 24&#xD;
      hours, all urine and stool will be collected for measurement of its calcium content.&#xD;
&#xD;
      Subsequently for the next five days, women will collect three urine specimens daily. Women&#xD;
      will then receive vitamin D to treat vitamin D deficiency. Once vitamin D repletion is&#xD;
      accomplished, all women will repeat their 24-hour visit and subsequent five-day urine&#xD;
      collections. Women will maintain vitamin D repletion by taking a twice monthly tablet (50,000&#xD;
      IU) of vitamin D2. To confirm vitamin D repletion and safety over the full one year study,&#xD;
      additional study visits will occur at 3, 6 and 12 months.&#xD;
&#xD;
      A bone density test at screening and twelve months will allow us to assess the effect of&#xD;
      vitamin D repletion on whole body bone mass and skeletal mass. At each GCRC stay, 3, 6 and 12&#xD;
      months, women will complete questionnaires regarding quality of life and functional status&#xD;
      and will perform the Timed Up and Go Test. Because we wish to maintain and confirm constant&#xD;
      calcium intake throughout the one- year study, women will complete a calcium questionnaire at&#xD;
      baseline, 3, 6 and 12 months.&#xD;
&#xD;
      With each subject's consent, we will collect one tube of blood and isolate its DNA. When&#xD;
      sufficient knowledge is available regarding the pathophysiologic mechanisms whereby genetic&#xD;
      polymorphisms impact calcium homeostasis, we will test for such DNA polymorphisms and relate&#xD;
      genetic information with other data collected on calcium homeostasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Intestinal Calcium Absorption From Baseline to One Month</measure>
    <time_frame>1 month</time_frame>
    <description>percent and true fractional calcium absorption</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Osteopenia</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Hypoparathyroidism</condition>
  <condition>Hypercalciuria</condition>
  <condition>Hypercalcemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Vitamin D2</other_name>
    <other_name>Ergocalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women at least five years past onset of menopause, defined as date of last menses&#xD;
&#xD;
          -  serum 25(OH)D 16-24 ng/ml by reverse phase HPLC&#xD;
&#xD;
          -  calcium intake &lt; or = 1,100 mg daily&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intake of &gt;1,100 mg of calcium per day through the combination of diet and supplements&#xD;
&#xD;
          -  Hypercalcemia (baseline serum calcium above the normal reference range)&#xD;
&#xD;
          -  Nephrolithiasis, documented in the medical record or by patient report&#xD;
&#xD;
          -  Inflammatory bowel disease, malabsorption, chronic diarrhea, or use of antibiotics&#xD;
             within the past month&#xD;
&#xD;
          -  Creatinine &gt;2.0 mg/dL&#xD;
&#xD;
          -  Hypercalciuria (baseline urine calcium: creatinine ratio &gt;0.25)&#xD;
&#xD;
          -  Current use of medications known to interfere with vitamin D and/or calcium&#xD;
             metabolism, including oral steroids or anticonvulsants&#xD;
&#xD;
          -  Ongoing or recent (past six months) use of bisphosphonates, estrogen compounds,&#xD;
             calcitonin or teriparatide, as these compounds may independently affect retention of&#xD;
             calcium within bone&#xD;
&#xD;
          -  Diagnosis of, or evidence for, osteomalacia, manifest by serum 25(OH)D &lt; 16 ng/ml or&#xD;
             the presence of at least two of the following blood tests: low calcium, low&#xD;
             phosphorus, or elevated alkaline phosphatase (23).&#xD;
&#xD;
          -  Prior adult clinical fragility fracture or baseline T-score below -3.0 at the lumbar&#xD;
             spine or femur&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen E Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hansen KE, Jones AN, Lindstrom MJ, Davis LA, Engelke JA, Shafer MM. Vitamin D insufficiency: disease or no disease? J Bone Miner Res. 2008 Jul;23(7):1052-60. doi: 10.1359/jbmr.080230.</citation>
    <PMID>18302509</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2007</study_first_posted>
  <results_first_submitted>July 6, 2012</results_first_submitted>
  <results_first_submitted_qc>September 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2012</results_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calcium Absorption</keyword>
  <keyword>Intestinal Absorption of Calcium</keyword>
  <keyword>Fractional Calcium Absorption</keyword>
  <keyword>Stable Calcium Isotopes</keyword>
  <keyword>Hypovitaminosis D</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Bone Mineral Density</keyword>
  <keyword>Physical Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Hypercalcemia</mesh_term>
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Hypoparathyroidism</mesh_term>
    <mesh_term>Hypercalciuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D</title>
          <description>Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D</title>
          <description>Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Intestinal Calcium Absorption From Baseline to One Month</title>
        <description>percent and true fractional calcium absorption</description>
        <time_frame>1 month</time_frame>
        <population>One subject's urine sample was mishandled, leaving 18 subjects with complete data for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intestinal Calcium Absorption From Baseline to One Month</title>
          <description>percent and true fractional calcium absorption</description>
          <population>One subject's urine sample was mishandled, leaving 18 subjects with complete data for analysis.</population>
          <units>percent calcium absorption</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D</title>
          <description>Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Karen Hansen</name_or_title>
      <organization>University of Wisconsin</organization>
      <phone>608-263-3457</phone>
      <email>keh@medicine.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

